| Literature DB >> 18385816 |
Domingos Dias Cicarelli1, Joaquim Edson Vieira, Fábio Ely Martins Benseñor.
Abstract
Septic shock is a severe inflammatory state caused by an infectious agent. Our purpose was to investigate serum amyloid A (SAA) protein and C-reactive protein (CRP) as inflammatory markers of septic shock patients. Here we evaluate 29 patients in postoperative period, with septic shock, in a prospective study developed in a surgical intensive care unit. All eligible patients were monitored over a 7-day period by sequential organ failure assessment (SOFA) score, daily CRP, SAA, and lactate measurements. CRP and SAA strongly correlated up to the fifth day of observation but were not good predictors of mortality in septic shock.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18385816 PMCID: PMC2277077 DOI: 10.1155/2008/631414
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Baseline characteristics of the patients.
|
|
|
|---|---|
| Age (years) | 65 ± 13.9 |
| Male sex | 45% |
| Weight (kg) | 63.5 ± 11.7 |
| APACHE II score | 19.8 ± 4.5 |
| SOFA score | 9.6 ± 2.3 |
|
| |
|
| (%) |
| Hypertension | 31 |
| Myocardial infarction | 13.7 |
| Diabetes | 13.7 |
| Liver disease | 6.9 |
| COPD | 6.9 |
| Cancer | 20.7 |
|
| |
|
| (%) |
| Multiple trauma (excluding head trauma) | 3.4 |
| Gastrointestinal surgery | 75.9 |
| Major vascular surgery | 6.9 |
| Thoracic surgery | 3.4 |
| Urologic surgery | 10.4 |
|
| |
|
|
|
| Mechanical ventilation | 4.0 ± 3.2 |
| Shock (use of vasopressor) | 4.2 ± 1.9 |
APACHE: acute physiology and chronic health evaluation, SOFA: sequential organ failure assessment, COPD: chronic obstructive pulmonary disease.
Microbiological characteristics of patients.
| Patient | Surgery/phatology | Antibiotics | Type of organism | Type of culture |
|---|---|---|---|---|
| 1 | Cholecistectomy/biliary abscess | Vanco + cefepime | S. aureus | Abscess culture |
| 2 | Empyema pleural drainage | Ceftriaxone + clindamycin | S. pyogenes | Pleural abscess culture |
| 3 | Cholecistectomy/biliary abscess | Ceftriaxone + metronidazole | — | Negative cultures |
| 4 | Cystectomy/pyuria | Ceftriaxone + metronidazole | — | Negative cultures |
| 5 | Aortic bypass/leg amputation | Ceftazidime + clindamycin | P. aeruginosa | Surgical site culture |
| 6 | Colectomy/cavity contamination | Ceftriaxone + metronidazole | — | Negative cultures |
| 7 | Calcaneal exposure fracture | Ciprofloxacin | E. faecalis | Surgical site culture |
| 8 | Pyonephrosis drainage | Ceftriaxone | K. pneumoniae | Urinary culture |
| 9 | Sigmoidectomy | Ceftriaxone + metronidazole | A. baumanii | Blood culture |
| 10 | Hemicolectomy | Ceftriaxone + metronidazole | Candida albicans | Blood culture |
| 11 | Enterectomy/mesenteric ischemia | Ceftriaxone + metronidazole | — | Negative cultures |
| 12 | Pancreatic-duodenal resection | Ceftriaxone | Serratia marcesens | BAL |
| 13 | Pancreatic-duodenal resection | Ceftriaxone + metronidazole | S. coag negative | Blood culture |
| 14 | Retroperitoneal abscess drainage | Cefepime + vanco + imipenem | P. aeruginosa | Blood culture |
| 15 | Abdominal aneurysm repair | Vanco + imipenem | S. aureus | Blood culture |
| 16 | Sigmoidectomy/perforative lesion | Ceftriaxone + metronidazole | Serratia marcesens | Ascite culture |
| 17 | Colectomy | Cefepime + vanco | S. aureus | Blood culture |
| 18 | Gastric ulcer | Ceftriaxone + metronidazole | — | Negative cultures |
| 19 | Cholecistectomy | Cipro + metronidazole | Escherichia coli | Urinary culture |
| 20 | Hemicolectomy | Cefepime + vanco + metro | E. cloacae | Blood culture |
| 21 | Enterectomy/cavity contamination | Vanco + imipenem | — | Negative cultures |
| 22 | Colectomy | Ceftriaxone + metronidazole | A. baumanii | Blood culture |
| 23 | Colectomy | Ceftriaxone + metronidazole | P. aeruginosa | Blood culture |
| 24 | Enterectomy/cavity contamination | Ceftriaxone + metronidazole | — | Negative cultures |
| 25 | Cervical abscess drainage | Imipenem + vanco + metro | K. pneumoniae | Blood culture |
| 26 | Sigmoidectomy/perforative lesion | Ceftriaxone + metronidazole | P. aeruginosa | Blood culture |
| 27 | Sigmoidectomy | Cefepime + metronidazole | S. aureus | Blood culture |
| 28 | Pyonephrosis drainage | Cefepime + metronidazole | — | Negative cultures |
| 29 | Colectomy | Ceftriaxone + metronidazole | P. aeruginosa | BAL |
Vanco: vancomycin, Cipro: ciprofloxacin, Metro: metronidazole, S. aureus: Staphylococcus aureus, S. pyogenes: Streptococcus pyogenes, P. aeruginosa: Pseudomonas aeruginosa, E. faecalis: Enterobacter faecalis, K. pneumoniae: Klebsiella pneumoniae, A. baumanii: Acinetobacter baumanii, S. coag negative: Staphylococcus coagulase negative, E. cloacae: Enterobacter cloacae, BAL: bronchoalveolar lavage.
SOFA, CRP, and SAA during the study period (mean ± SD).
| Day 0 | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
|---|---|---|---|---|---|---|---|---|
| SOFA | 9.6 ± 2.3 | 10 ± 2.6 | 9.4 ± 4.1 | 9.8 ± 4.4 | 9.4 ± 4.2 | 9.9 ± 3.7 | 8.7 ± 4.1 | 8.6 ± 3.5 |
| CRP | 19.8 ± 8.4 | 20.9 ± 9.1 | 16.3 ± 6.2 | 13.2 ± 5.9 | 11.8 ± 7.7 | 12.7 ± 11.2 | 11.9 ± 8.3 | 10.0 ± 4.4 |
| SAA | 47 ± 39.8 | 37.2 ± 28.1 | 29 ± 21.48 | 22.7 ± 18.4 | 18.6 ± 20.8 | 24.7 ± 25.8 | 22.2 ± 20.5 | 21.7 ± 16.8 |
SOFA: sequential organ failure assessment, CRP: C-reactive protein, SAA: serum amyloid A. ANOVA. Equal variance test: SOFA P = .956, CRP P = .062, SAA P = .055.
Pearson coefficient for SAA and CPR.
|
|
| |
|---|---|---|
| Day 0 | 0.682 | .0001 |
| Day 1 | 0.660 | .0004 |
| Day 2 | 0.464 | .034 |
| Day 3 | 0.529 | .024 |
| Day 4 | 0.651 | .0062 |
| Day 5 | 0.778 | .0028 |
| Day 6 | 0.578 | .628 |
| Day 7 | 0.081 | .822 |
Maximum likelihood, Wald statistic (P-value).
| APACHE II | SOFA | CPR | SAA | |
|---|---|---|---|---|
| Day 0 | 3.46 (.06) | 2.46 (.11) | 0.02 (.89) | 1.91 (.17) |
| Day 1 | 3.06 (.08) | 3.50 (.06) | 1.01 (.31) | 0.03 (.86) |
| Day 3 | 0.00 (.98) | 0.00 (.98) | 0.00 (.98) | 0.00 (.98) |
Figure 1CRP evolution of survivors and nonsurvivors during the first week (NS). NS: not statistically significant.
Figure 2SAA evolution of survivors and nonsurvivors during the first week (NS). NS: not statistically significant.